Ongoing Clinical Trials for Follicular Lymphoma Grade I, II, III Recurrent
This article provides information about an ongoing clinical trial investigating new treatment options for patients with recurrent follicular lymphoma grades I, II, or III. The trial is exploring the use of mosunetuzumab, a bispecific antibody designed to help the immune system target cancer cells, specifically for patients whose disease has returned or worsened within 24 months after their first treatment. The trial is being conducted across several countries in Northern Europe. (Also known as: Follicle centre lymphoma follicular grade I II III recurrent)
Clinical trial locations
- Denmark
- Finland
- Norway
- Sweden
Study of Mosunetuzumab for Patients with Early Relapse of Follicular Lymphoma
This trial is investigating mosunetuzumab as a treatment option for patients whose follicular lymphoma has returned or progressed within 24 months of starting their initial treatment. Mosunetuzumab is a bispecific antibody, a specialized type of protein that works by helping the body’s immune system recognize and destroy cancer cells. The medication is administered as a subcutaneous injection, meaning it is given under the skin rather than into a vein.
Who can participate:
- Adults aged 18 years or older
- Patients with follicular lymphoma grades 1-3a who have experienced disease relapse or progression within 24 months of starting their first treatment, or whose disease did not respond to initial treatment
- Patients with at least one measurable area of cancer with a longest diameter greater than 15mm
- Patients with a WHO performance status of 0-2, which measures the ability to carry out daily activities. Those with a status worse than 2 may still be considered if the lymphoma is causing the reduced ability
- Patients must be able to provide written informed consent, demonstrating they understand the trial and agree to participate
Who cannot participate:
- Patients with other types of cancer besides follicular lymphoma
- Patients who have not experienced disease relapse or worsening within 24 months of starting first treatment
- Patients who are not suitable candidates for the treatment being tested
- Patients unable to follow study procedures or attend required visits
- Patients with certain medical conditions that might interfere with the study treatment
- Women who are pregnant or breastfeeding
- Patients who have recently participated in another clinical trial
- Patients with a history of severe allergic reactions to similar medications
Focus and goals:
The primary goal of this trial is to evaluate how effective mosunetuzumab is as a second-line treatment for patients with early relapse of follicular lymphoma. The study will follow participants for up to four years to observe progression-free survival, which is the length of time during and after treatment that the cancer does not worsen.
The treatment involves 8 cycles of mosunetuzumab administered at specific intervals. Throughout the study, participants will undergo regular monitoring, including imaging tests such as FDG-PET-CT scans, to assess how the lymphoma responds to treatment. Some participants may receive a placebo instead of the active medication to allow researchers to compare the effects.
Researchers will also measure the overall response rate, which indicates how well the lymphoma responds to treatment, the complete response rate, and the duration of response. The study aims to gather information about the safety and tolerability of mosunetuzumab, helping to determine whether this treatment could be a valuable option for patients with recurrent follicular lymphoma.
Investigational drug:
Mosunetuzumab is a monoclonal antibody that targets specific proteins on the surface of cancer cells. By doing so, it helps the immune system recognize and destroy these cells. This medication is given as a subcutaneous injection under the skin and is being specifically studied for its potential to treat follicular lymphoma that has returned or worsened after initial treatment.
Summary
Currently, there is one ongoing clinical trial for patients with recurrent follicular lymphoma grades I, II, or III. This trial is being conducted across four Northern European countries: Sweden, Denmark, Finland, and Norway. The study focuses on patients who have experienced early relapse within 24 months of their first treatment and investigates the use of mosunetuzumab, a bispecific antibody designed to enhance the immune system’s ability to fight cancer cells. The trial aims to provide valuable information about this treatment approach and its potential to improve outcomes for patients facing early disease recurrence.